First - Line Osimertinib May Up Survival in EGFR - Mutated NSCLC

For previously untreated disease, overall survival longer with osimertinib versus comparator EGFR - TKIs
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news